Compugen Showcases Innovative Research at the Single Cell Genomics 2025 Conference
Compugen Ltd., a clinical-stage company focused on cancer immunotherapy, is set to highlight its latest research findings at the upcoming Single Cell Genomics 2025 Conference from September 15 to 17 in Stockholm, Sweden. The conference is a significant event that gathers leading researchers and experts in the field of genomics to discuss advancements and innovations that could shape the future of medicine.
At this conference, Compugen is expected to present findings that showcase its advanced computational capabilities, particularly in the area of spatial context within complex cancer biology. This research is crucial as it aims to enhance drug discovery efforts and refine therapeutic strategies that could ultimately benefit patients fighting cancer.
One of the key highlights of Compugen's presentation is a poster titled "Bin2Niche: A Spatial Transcriptomics Framework Reveals Immune-defined Epithelial Niches in MSI Colorectal Cancer." The lead author, Dr. Roy Granit, who serves as the Senior Director and Head of Computational Discovery at Compugen, will present the findings on September 15, 2025, at 2:10 PM CET. Following the conference, the poster will also be made available on Compugen's website, providing broader accessibility to those interested in the details of this innovative research.
Compugen is recognized for its pioneering work leveraging artificial intelligence and machine learning (AI/ML) in predictive computational discovery, which has paved the way for new drug targets and biological pathways. The company is currently developing its proprietary platform, Unigen™, designed to empower the identification of novel therapeutic strategies in cancer treatment.
Currently, Compugen has several promising candidates in various stages of clinical development, with two main products in Phase 1 trials. These include COM701, an anti-PVRIG antibody which holds potential as a first-in-class treatment, and COM902, designed to target TIGIT for solid tumors. In addition, the company is in collaboration with AstraZeneca for the development of a PD-1/TIGIT bispecific antibody, Rilvegostomig, which is currently in Phase 3 development.
Moreover, GS-0321, another key product and a high-affinity anti-IL-18 binding protein antibody, is also advancing through Phase 1 trials, having been licensed to Gilead. Together, these developments underscore Compugen's commitment to addressing the complex challenges inherent in cancer treatment through innovative research and cutting-edge technology.
As the Single Cell Genomics Conference approaches, there's palpable excitement in the scientific community regarding the potential insights Compugen's research could offer, not only for the company but for the entire landscape of cancer therapeutics. This event represents an opportunity for professionals and researchers to engage with the latest findings, discuss potential collaborations, and understand the evolving role of data in optimizing cancer treatments.
With its headquarters situated in Israel and a presence in San Francisco, California, Compugen continues to expand its footprint in the cancer immunotherapy market, ensuring that its groundbreaking research makes a significant impact globally.
In summary, Compugen's participation at the Single Cell Genomics Conference is not just a presentation of findings; it’s part of a larger narrative that reflects the intersection of technology, science, and healthcare innovation aimed at transforming cancer treatment methodologies for the betterment of patients worldwide.
At this conference, Compugen is expected to present findings that showcase its advanced computational capabilities, particularly in the area of spatial context within complex cancer biology. This research is crucial as it aims to enhance drug discovery efforts and refine therapeutic strategies that could ultimately benefit patients fighting cancer.
One of the key highlights of Compugen's presentation is a poster titled "Bin2Niche: A Spatial Transcriptomics Framework Reveals Immune-defined Epithelial Niches in MSI Colorectal Cancer." The lead author, Dr. Roy Granit, who serves as the Senior Director and Head of Computational Discovery at Compugen, will present the findings on September 15, 2025, at 2:10 PM CET. Following the conference, the poster will also be made available on Compugen's website, providing broader accessibility to those interested in the details of this innovative research.
Compugen is recognized for its pioneering work leveraging artificial intelligence and machine learning (AI/ML) in predictive computational discovery, which has paved the way for new drug targets and biological pathways. The company is currently developing its proprietary platform, Unigen™, designed to empower the identification of novel therapeutic strategies in cancer treatment.
Currently, Compugen has several promising candidates in various stages of clinical development, with two main products in Phase 1 trials. These include COM701, an anti-PVRIG antibody which holds potential as a first-in-class treatment, and COM902, designed to target TIGIT for solid tumors. In addition, the company is in collaboration with AstraZeneca for the development of a PD-1/TIGIT bispecific antibody, Rilvegostomig, which is currently in Phase 3 development.
Moreover, GS-0321, another key product and a high-affinity anti-IL-18 binding protein antibody, is also advancing through Phase 1 trials, having been licensed to Gilead. Together, these developments underscore Compugen's commitment to addressing the complex challenges inherent in cancer treatment through innovative research and cutting-edge technology.
As the Single Cell Genomics Conference approaches, there's palpable excitement in the scientific community regarding the potential insights Compugen's research could offer, not only for the company but for the entire landscape of cancer therapeutics. This event represents an opportunity for professionals and researchers to engage with the latest findings, discuss potential collaborations, and understand the evolving role of data in optimizing cancer treatments.
With its headquarters situated in Israel and a presence in San Francisco, California, Compugen continues to expand its footprint in the cancer immunotherapy market, ensuring that its groundbreaking research makes a significant impact globally.
In summary, Compugen's participation at the Single Cell Genomics Conference is not just a presentation of findings; it’s part of a larger narrative that reflects the intersection of technology, science, and healthcare innovation aimed at transforming cancer treatment methodologies for the betterment of patients worldwide.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.